• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
#

Drugs

: 6
The main risk associated with the failure of the trials is a “potential loss of confidence” in the company, according to Jefferies: based on their information, AstraZeneca’s management was confident in the effectiveness of the drug’s development / Photo: Declan Sun / unsplash
News·09.07.2026 22:00
AstraZeneca lost $27 billion in market capitalization in a single day: its drug failed clinical trials
  • AZN
  • IONS
Galderma shares plummeted 6% on the Zurich Stock Exchange / Photo: Body Stock / Shutterstock
News·01.07.2026 18:39
Shares of pharmaceutical company Galderma plummeted: The U.S. has halted sales of a Botox generic
  • ABBV
  • GALD.SW
Generate Bio has listed on the Nasdaq with the ticker GENB / Photo: Photoroyalty/Shutterstock
News·27.02.2026 15:00
IPO Generate Biomedicines: shares of AI drug development platform become available
  • GENB
Pfizer will buy a company that develops obesity remedies. Its shares soared 60%
News·22.09.2025 17:58
Pfizer will buy a company that develops obesity remedies. Its shares soared 60%
  • PFE
Shares in biotech Sarepta soar after FDA allows shipments of Elevidys to resume
Small Caps·30.07.2025 11:46
Shares in biotech Sarepta soar after FDA allows shipments of Elevidys to resume
  • SRPT
Eli Lilly is entering a market valued at $30 billion, can it beat the competition?
News·24.06.2025 04:17
Eli Lilly is entering a market valued at $30 billion, can it beat the competition?
  • LLY
  • NVO
  • AZN
X-channel

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026